PARP1 and Ewing sarcoma: Together, this implies that the underlying oncogenic mechanisms of ES are complex and that combining PARP inhibition with chemotherapy is not sufficient to create a therapeutic window that would allow ES cells to be preferentially sensitised over healthy patient cells.